INKmune - INmune Bio
Alternative Names: INB 16; INKmuneLatest Information Update: 18 Sep 2025
At a glance
- Originator INmune Bio
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
- Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes; Ovarian cancer; Renal cancer
Most Recent Events
- 18 Sep 2025 Discontinued - Phase-I for Acute myeloid leukaemia in United Kingdom, Greece (IV) before September 2025 (INmune Bio pipeline, September 2025)
- 18 Sep 2025 Discontinued - Phase-I for Myelodysplastic syndromes in Greece, United Kingdom (IV) before September 2025 (INmune Bio pipeline, September 2025)
- 18 Sep 2025 Discontinued - Phase-I for Ovarian cancer in USA (IV) before September 2025 (INmune Bio pipeline, September 2025)